1st treatment: total 8 times, which include weekly injection for 4 times followed by bi-weekly injection for 4 times&gt

14 trials

Sponsors

Kurume University Cancer Vaccine Center, Kurume University Center Vaccine Center

Conditions

Biliary cancer (Cholangiocell carcinoma,Gallbladder cancer and Biliary tract cancer)Colon cancerPancreatic cancerProstate cancerRenal cell carcinomaSarcomaUrotherial cancerbrest cancer

Phase 2

Phase II clinical trial of personalized peptide vaccination for Pancreatic cancer patients

Active, not recruitingJPRN-UMIN000002908

Kurume University Center Vaccine CenterPancreatic cancer

Start: 2009-12-01Target: 100Updated: 2026-06-29

Phase II clinical trial of personalized peptide vaccination for Biliary cancer (Cholangiocell carcinoma,Gallbladder cancer and Biliary tract cancer) patients

Active, not recruitingJPRN-UMIN000002907

Kurume University Cancer Vaccine CenterBiliary cancer (Cholangiocell carcinoma,Gallbladder cancer and Biliary tract cancer)

Start: 2009-12-01Target: 100Updated: 2026-06-29

Phase II clinical trial of personalized peptide vaccination for malignant brain tumor patients

Active, not recruitingJPRN-UMIN000002906

Kurume University Cancer Vaccine Centermalignant brain tumor

Start: 2009-12-01Target: 100Updated: 2026-06-29

Phase II clinical trial of personalized peptide vaccination for Colon cancer patients

Active, not recruitingJPRN-UMIN000002987

Kurume University Cancer Vaccine CenterColon cancer

Start: 2010-01-01Target: 100Updated: 2026-06-29

Phase II clinical trial of personalized peptide vaccination for gastric cancer patients

Active, not recruitingJPRN-UMIN000002985

Kurume University Cancer Vaccine Centergastric cancer

Start: 2010-01-01Target: 100Updated: 2026-06-29

Phase II clinical trial of personalized peptide vaccination for lung cancer patients

Active, not recruitingJPRN-UMIN000002984

Kurume University Cancer Vaccine Centerlung cancer

Start: 2010-01-01Target: 100Updated: 2026-06-29

Phase II clinical trial of personalized peptide vaccination for liver cancer patients

Active, not recruitingJPRN-UMIN000003029

Kurume University Cancer Vaccine Centerliver cancer

Start: 2010-01-01Target: 100Updated: 2026-06-29

Phase II clinical trial of personalized peptide vaccination for Prostate cancer patients

Active, not recruitingJPRN-UMIN000003028

Kurume University Cancer Vaccine CenterProstate cancer

Start: 2010-01-01Target: 100Updated: 2026-06-29

Phase II clinical trial of personalized peptide vaccination for Renal cell carcinoma patients

Active, not recruitingJPRN-UMIN000003027

Kurume University Cancer Vaccine CenterRenal cell carcinoma

Start: 2010-01-01Target: 100Updated: 2026-06-29

Phase II clinical trial of personalized peptide vaccination for sarcoma patients

Active, not recruitingJPRN-UMIN000003060

Kurume University Cancer Vaccine CenterSarcoma

Start: 2010-01-01Target: 100Updated: 2026-06-29

Phase II clinical trial of personalized peptide vaccination for urotherial cancer patients

Active, not recruitingJPRN-UMIN000003059

Kurume University Cancer Vaccine CenterUrotherial cancer

Start: 2010-01-01Target: 100Updated: 2026-06-29

Phase II clinical trial of personalized peptide vaccination for ovarian, tubal, and peritoneal cancers patients

Active, not recruitingJPRN-UMIN000003083

Kurume University Cancer Vaccine Centerovarian, tubal, and peritoneal cancers

Start: 2010-01-01Target: 100Updated: 2026-06-29

Phase II clinical trial of personalized peptide vaccination for brest cancer patients

Active, not recruitingJPRN-UMIN000003081

Kurume University Cancer Vaccine Centerbrest cancer

Start: 2010-01-01Target: 100Updated: 2026-06-29

Phase II clinical trial of personalized peptide vaccination for cervical cancer patients

Active, not recruitingJPRN-UMIN000003082

Kurume University Cancer Vaccine Centercervical cancer

Start: 2010-01-01Target: 100Updated: 2026-06-29

Related Papers

Abstract P4-06-06: Comparison of the immunological and clinical effect of personalized peptide vaccination for patients with breast cancer

Cancer Research2019-02-15

Plasma Levels of High-Mobility Group Box 1 during Peptide Vaccination in Patients with Recurrent Ovarian Cancer

Journal of Immunology Research2017-01-019 citations